Intensity Therapeutics, Inc. is a private, Connecticut-based company founded to develop therapeutics using its proprietary DfuseRx℠ platform. The Company’s platform technology can rapidly identify a tissue dispersion and cell penetrating anti-cancer formulation for a given tumor type. Intensity’s technology approach creates a product with sufficient potency to destroy a patient’s primary tumors and train the immune system to hunt and kill metastases.
In vivo (mouse) data generated indicates that Intensity’s products and methods can effectively kill cancer cells, cause the regression of large tumors to baseline, extend life, and immunize animals against tumor recurrence. Intensity’s lead product is being studied under a Collaborative Research and Development Agreement(CRADA) with the National Cancer Institute (NCI) branch of the National Institute of Health.
Intensity has initiated its first human clinical trial to study the effects of INT230-6 in solid tumors. IT-01 is entitled A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers. The trial aims to enroll approximately 60 patients with different types advanced solid tumor malignancies in a multicycle dosing regimen. The study will be conducted in multiple countries and includes a cohort combining INT230-6 with an anti-PD-1 antibody.
The most up-to-date information on Intensity Therapeutics can be found on its website,intensitytherapeutics.com.